New Study Shows Combining Peregrine's Bavituximab With An Apoptosis-Inducing Agent Ca
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) announced the publication of new data highlighting the tumor-killing potential of its lead phosphatidylserine (PS)-targeting antibody bavituximab in combination with an agent that induces apoptosis, or programmed cell death...
More... |
All times are GMT -7. The time now is 06:15 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021